Article
Flutamide and biomarkers in women at high risk for ovarian cancer: preclinical and clinical evidence.
Cancer prevention research (Philadelphia, Pa.) - 1 Sept 2014
Gruessner Christine, Gruessner Angelika, Glaser Katherine, AbuShahin Nisreen, Zhou Yi, Laughren Cynthia, Wright Heather, Pinkerton Samantha, Yi Xiaofang, Stoffer Jha'nae, Azodi Masoud, Zheng Wenxin, Chambers Setsuko K
Abstract excerpt
We hypothesized that (i) preclinical biologic evidence exists for the role of androgens in ovarian cancer development and (ii) flutamide treatment of women at high risk for ovarian cancer may identify meaningful tissue biomarkers of androgen action and of ovarian cancer initiation. We showed that androgen ablation of male mice led to a 24-fold decrease in tumor burden from serous ovarian cells. In a phase II...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.